Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites

Drug Metabolism and Disposition

Volumn 29, Issue 7, 2001, Pages 936-944

  Ekins, Sean ^a   De Groot, Marcel J ^b   Jones, Jeffrey P ^c  

^a ELI LILLY AND COMPANY   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4;

ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME SUBSTRATE; MOLECULAR MODEL; PHARMACOPHORE; PRIORITY JOURNAL; SHORT SURVEY; STRUCTURE ACTIVITY RELATION;

BINDING SITES; CYTOCHROME P-450 ENZYME SYSTEM; MODELS, CHEMICAL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034962557     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (114)

1. The cytochrome-P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population
2. A comparative molecular field analysis study of obtusfoliol 14α-methyl demethylase inhibitors
3. Characterization and catalytic properties of the sterol 14α-demethylase from Mycobacterium tuberculosis
4. Theoretical investigations on the role of steroidskeleton C4=C5 unsaturation in competitive aromatase inhibition
5. Application of MS-WHIM Descriptors 1. Introduction of new molecular surface properties and 2. Prediction of binding affinity data
6. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
7. Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme. Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding
8. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins
9. Molecular modeling of mammalian cytochrome P450s
10. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6
11. Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for CYP2D6
12. A refined substrate model for human cytochrome P450 2D6
13. Extension of a predictive substrate model for human cytochrome P4502D6
14. Computer prediction and experimental validation of cytochrome P450-2D6 dependent oxidation of GBR 12909 (1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine)
15. Modeling the active site of cytochrome P450s and glutathione S-transferases, two of the most important biotransformation enzymes
16. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102 and P450 108
17. Characterization of the mouse lanosterol 14α-demethylase (CYP51), a new member of the evolutionarily most conserved cytochrome P450 family
18. Theoretical investigation of substrate specificity for cytochromes P450 1A2, P450 IID6 and P450 IIIA4
19. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes
20. Defective N-oxidation of sparteine in man: A new pharmacogenetic effect
21. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors
22. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of inhibitors for CYP3A4
23. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors
24. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6
25. Three dimensional quantitative structure activity relationship (3D-QSAR) analysis of CYP3A4 substrates
26. Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millennium
27. Progress in predicting human ADME parameters in silico
28. The role of CYP2B6 in human xenobiotic metabolism
29. The active site of cytochrome P-450 nifedipine oxidase: A model-building study
30. Quinolone antibacterial agents: Relationship between structure and in vitro inhibition of human cytochrome P450 isoform CYP1A2
31. Recent success stories leading to commercializable bioactive compounds with the aid of traditional QSAR procedures
32. m
33. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase
34. Enzymatic determinants of the substrate specificity of CYP2C9: Role of B′-C loop residues in providing the π-stacking anchor site for warfarin binding
35. Quantitative relationships between lipophilic character and drug metabolism
36. Structure-activity correlations in the metabolism of drugs
37. Quantitative structure-activity relationships of cytochrome P-450
38. The indole-2-carboxamide glycogen phosphorylase inhibitor, CP-320,626, lowers plasma cholesterol in experimental animals through its action as lanosterol 14α-demethylase (CYP51) inhibitor
39. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9
40. The nuclear orphan receptor CAR-retinoid x receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene
41. A three dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation
42. A three dimensional model of lanosterol 14α-demethylase of Candida albicans and its interaction with azole antifungals
43. Putative active site model for CYP2C9 (tolbutamide hydroxylase)
44. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase)
45. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9
46. An orphan nuclear receptor activated by pregnanes defines a novel steroid signalling pathway
47. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2
48. Predicting the cytochrome P450 mediated metabolism of xenobiotics
49. A predictive model for substrates of cytochrome P450-debrisoquine (2D6)
50. Characteristics of the heterologously expressed human lanosterol 14α-demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and candida albicans CYP51 with azole antifungal agents
51. Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids
52. The human orphan receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions
53. Quantitative structure activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1)
54. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics
55. Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles
56. Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate
57. Erratum to Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate
58. Molecular modelling of CYP3A4 from an alignment with CYP102: Identification of key interactions between putative active site residues and CYP3A-specific chemicals
59. Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes
60. Molecular modelling of the phenobarbital-inducible P450 isoforms: CYP2B1, CYP2B4 and CYP2B6 by homology with the substrate-bound CYP102 crystal structure, and evaluation of CYP2B substrate binding affinity
61. Molecular modelling of lanosterol 14αdemethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: Quantitative structure-activity relationships (QSARs) within two related series of antifungal azole derivatives
62. Regioselective hydroxylation of debrisoquine by cytochrome P450 2D6: Implications for active site modeling
63. Investigation of substrate structure activity relationships (SSAR) for cytochrome P450 2C19
64. Substrate structure activity relationships (SSAR) of benzodiazepines for cytochrome P450 2C19
65. 3D-QSAR methods on the basis of ligand-receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands
66. Active site topology of human cytochrome P4502E1
67. Polymorphic oxidation of debrisoquine in man
68. The substrate binding site of human liver cytochrome P4502C9: An approach using designed tienilic acid derivatives and molecular modeling
69. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: Molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP2C9
70. The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation
71. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
72. St. John's Wort induces hepatic drug metabolism through activation of the pregnane X receptor
73. Molecular shape and QSAR analyses of a family of substituted dichlorodiphenyl aromatase inhibitors
74. Steady state enzyme velocities that are independent of [enzyme]: An important behavior in many membrane and particle-bound states
75. Design, synthesis, and characterization of 7-methoxy-4-(aminomethyl)coumarin as a novel and selective cytochrome P450 2D6 substrate suitable for high-throughput screening
76. Three-dimensional quantitative structure-activity relationships of steroid inhibitors
77. Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450
78. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes
79. A comparative molecular field analysis of cytochrome P450 2A5 and 2A6 inhibitors
80. Comparative molecular field analysis of compounds with CYP2A5 binding affinity
81. The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450
82. Crystal structure of substrate-free Pseudomonas putida cytochrome P-450
83. A refined 3-dimensional QSAR of P4502C9
84. Comparative molecular field analysis of non steroidal aromatase inhibitors related to fadrozole
85. Comparative molecular field analysis of non-steroidal aromatase inhibitors: An extended model for two different structural classes
86. An approach to QSAR of 16-substituted pregnenolones as microsomal enzyme inducers
87. Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function
88. Theoretical study on the metabolism of caffeine by cytochrome P-450 1A2 and its inhibition
89. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells
90. Properties of cytochrome P450 isoenzymes and their substrates. Part 1: Active site characteristics
91. Properties of cytochrome P450 isoenzymes and their substrates. Part 2: Properties of cytochrome P450 substrates
92. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes
93. Conformational modulation of human cytochrome P450 2E1 by ethanol and other substrates: A CO flash photolysis study
94. New aromatase inhibitors, synthesis and biological activity of aryl-substituted pyrrolizine and indolizine derivatives
95. Entwicklung von strukturmodellen für substrate und inhibitoren von cytochrom P-450IID1 mit hilfe von molecular modeling und in-vitro-hemmungsmessungen
96. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: Molecular modeling and inhibition studies
97. Molecular modeling of mammalian cytochromes P450: Application to study enzyme function
98. Molecular modeling of cytochrome P4503A4
99. Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450
100. Molecular basis of P450 inhibition and activation implications for drug development and drug therapy
101. Molecular modeling of azole antifungal agents active against Candida albicans. 1. A comparative molecular field analysis study
102. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone
103. Development of pharmacophore alignment models as input for comparative molecular field analysis of a diverse set of azole antifungal agents
104. 14αDM inhibiting azole antifungal agents
105. Approach to detect substrates suitable to measure the coumarin 7-hydroxylase (Cyp 2a-5)-structure-activity relationships
106. SG1)
107. Structure-dependent induction of CYP1A by polychlorinated biphenyls in hepatocytes of cynomolgus monkeys (Macaca fascicularis)
108. Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity
109. Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds
110. Mammalian microsomal cytochrome P450 monooxygenase: Structural adaptations for membrane binding and functional diversity
111. Substrate specificity of human liver cytochrome P450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling
112. The human hepatic cytochromes P450 involved in drug metabolism
113. Sterol 14-demethylase P450 (CYP51) provides a breakthrough for the discussion on the evolution of cytochrome P450 gene superfamily
114. Metabolic interactions of selected antimalarial and nonntimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes